These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
320 related items for PubMed ID: 22661319
1. Sunitinib in pancreatic neuroendocrine tumors. Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, Faivre S. Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319 [Abstract] [Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. Bisht S, Feldmann G, Brossart P. Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):777-88. PubMed ID: 23590356 [Abstract] [Full Text] [Related]
3. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Faivre S, Ronot M, Dreyer C, Serrate C, Hentic O, Bouattour M, Bruno O, Couvelard A, Vilgrain V, Raymond E. Target Oncol; 2012 Jun; 7(2):127-33. PubMed ID: 22585430 [Abstract] [Full Text] [Related]
4. Sunitinib malate for the treatment of pancreas malignancies--where does it fit? Mankal P, O'Reilly E. Expert Opin Pharmacother; 2013 Apr; 14(6):783-92. PubMed ID: 23458511 [Abstract] [Full Text] [Related]
5. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. N Engl J Med; 2011 Feb 10; 364(6):501-13. PubMed ID: 21306237 [Abstract] [Full Text] [Related]
6. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, Metrakos P, Hörsch D, Mundayat R, Reisman A, Wang Z, Chao RC, Raymond E. Target Oncol; 2016 Dec 10; 11(6):815-824. PubMed ID: 27924459 [Abstract] [Full Text] [Related]
9. Sunitinib: in advanced, well differentiated pancreatic neuroendocrine tumors. Deeks ED, Raymond E. BioDrugs; 2011 Oct 01; 25(5):307-16. PubMed ID: 21942915 [Abstract] [Full Text] [Related]
10. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S. Target Oncol; 2012 Sep 01; 7(3):173-81. PubMed ID: 22923165 [Abstract] [Full Text] [Related]
11. Activity of sunitinib in patients with advanced neuroendocrine tumors. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. J Clin Oncol; 2008 Jul 10; 26(20):3403-10. PubMed ID: 18612155 [Abstract] [Full Text] [Related]
12. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C, Kondo S, Mizuno N, Hara K, Sawaki A, Hashigaki S, Kimura N, Murakami M, Ohki E, Chao RC, Imamura M. Invest New Drugs; 2013 Oct 10; 31(5):1265-74. PubMed ID: 23269537 [Abstract] [Full Text] [Related]
13. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. BMJ Open; 2015 May 19; 5(5):e008248. PubMed ID: 25991462 [Abstract] [Full Text] [Related]
14. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Yoo C, Cho H, Song MJ, Hong SM, Kim KP, Chang HM, Chae H, Kim TW, Hong YS, Ryu MH, Kang YK, Kim SC, Ryoo BY. Cancer Chemother Pharmacol; 2017 Jan 19; 79(1):139-146. PubMed ID: 27942928 [Abstract] [Full Text] [Related]
18. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours. Yim KL. Endocrine; 2011 Oct 19; 40(2):181-6. PubMed ID: 21870172 [Abstract] [Full Text] [Related]
19. Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. Capozzi M, VON Arx C, DE Divitiis C, Ottaiano A, Tatangelo F, Romano GM, Tafuto S, (On behalf of ENETS Center of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples, Italy). Anticancer Res; 2016 Oct 19; 36(10):5025-5030. PubMed ID: 27798861 [Abstract] [Full Text] [Related]
20. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP. J Med Econ; 2012 Oct 19; 15 Suppl 1():55-64. PubMed ID: 22881362 [Abstract] [Full Text] [Related] Page: [Next] [New Search]